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Conclusions: We have demonstrated that treatment with CS is capable
to reduce PBMC inﬂammation in rabbits in which chronic arthritis aggra-
vates vascular lesions associated to atherosclerosis. CS evoked a clear
improvement in the inﬂammatory response of the synovial membrane,
as well as a decrease in the synovial histopathological lesions. Our
results suggest that this drug may have beneﬁcial effects on the treatment
of inﬂammatory synovitis probably acting through the NFkB depending
pathway.
A36 DIFFERENTIAL EFFECTS OF TUMOR NECROSIS FACTOR-a
AND INTERLEUKIN-1b IN HUMAN CHONDROCYTES. A 2-DE
ELECTROPHORESIS APPROACH
B. Cillero-Pastor, M.J. Lo´pez-Armada, C. Ruiz-Romero, J. Mateos,
B. Lema, F. Galdo, F.J. Blanco. Osteoarticular and Aging Research
Laboratory. Biomedical Research Center, INIBIC-Hospital Universitario
Juan Canalejo, Corun˜a, SPAIN
Purpose: Il-1b and TNF-a are cytokines that have always been grouped
into the pro-inﬂammatory cytokine class. In some pathologic scenarios,
as in apoptotic environment, chondrocytes respond in a different way de-
pending on what cytokine is present. It is not clear the exact mechanisms
by they exercise their different functions in the chondrocyte. The present
study, analyzes the differences in protein expression patterns between
both cytokines in order to understand the development of rheumatic
pathologies.
Methods: Human normal chondrocytes were isolated from cartilage ob-
tained from autopsies without history of joint disease. Chondrocytes were
incubated for 48 hours in basal conditions, with Il-1b (5 ng/ml) or TNF-
a (10 ng/ml), and cellular protein extracts were obtained. A pool of four
patients in each condition, by duplicate, was made and resolved by 2-DE.
Protein spots were visualized with Sypro for comparative analyses or
with Coomassie stain for protein identiﬁcation. Qualitative and quantitative
analysis were made with PD-QUEST software. After that, protein spots
were identiﬁed by mass spectrometry using MALDI-TOF/TOF technology.
Validation of identiﬁed spots was made by real time PCR, western blot
and inmunoﬂuorescence.
Results: Different comparative analyses were made in the spots that
were matched in every member. We compared protein proﬁles between
basal and Il-1b, basal and TNF-a and between Il-1b and TNF-a conditions.
We found a different regulation in the expression ratios of cytoskeleton
proteins, modulation of transcription, metabolism, energy production and
stress responses between basal and Il-1b as well as, basal and TNF-a
stimulated cells. In addition to this, comparing both cytokines, this table
shows the qualitative differences in terms of presence (+) or absence (−),
between Il-1b and TNF-a conditions. Also, quantitative differences were
found in Tryptophanil tRNA synthethase, Translation initiation factor 3,
Interferon-induced GTP-binding protein and Argininosuccinate synthase,
that were up-regulated more than two fold in the TNF-a treated cells,
respect to Il-1b condition. On the other hand, proteins such as Antisense
basic ﬁbroblast growth factor or Triose phosphate isomerise, were down-
regulated in the TNF-a situation with a ratio of 0.4 (where Il-1b=1).
These differences affect principally to metabolic chondrocyte activity,
transcription and protein modiﬁcations.
PROT PAR12 P58 PSB3 PSME2 LDHB ACSL4 PBEF MDHM G3P ENOA MATN ANX5
TNFa/Il-1b −/+ −/+ +/− −/+ −/+ −/+ −/+ −/+ −/+ +/− −/+ −/+
Conclusions: Our studies indicate that the cytokines, Il-1b and TNF-a,
have different protein expression patterns in human normal chondrocytes
in culture. This study will help us to understand the role that each member
plays in pathologic processes that affects chondrocytes.
A37 AGGRECANASE CLEAVAGE IN THE INTERGLOBULAR
DOMAIN OF AGGRECAN IS MARKEDLY ELEVATED IN
ACUTE ARTHRITIS, OSTEOARTHRITIS AND AFTER KNEE
INJURY
S. Larsson, A. Struglics, M. Hansson, L.S. Lohmander. Lund University,
Lund, SWEDEN
Purpose: Aggrecanase cleavage at the 373Glu-374Ala bond in the inter-
globular domain of aggrecan, releasing N-terminal 374ARGS fragments,
is an early key event in arthritis and joint injuries. Here we quantify the
levels of aggrecan and aggrecan ARGS fragments in synovial ﬂuid from
knee healthy subjects and from patients with acute arthritis, knee injury
and knee osteoarthritis (OA) with the aim of verifying the pathological role
of aggrecanase cleavage at this site.
Methods: Knee synovial ﬂuid (SF) from 26 knee healthy individuals
(REF) and 269 patients were obtained in a cross sectional study. Patient
groups were acute arthritis (AA; n = 48), knee injury (KI; n = 192) and
OA (n = 29). The KI group was divided into three subgroups by time
after injury: 0−8 weeks (KI-1; n = 64), 9−52 weeks (KI-2; n = 58) and
>1 year (KI-3; n = 70). Aggrecan fragments with the N-terminal 374ARGS
were assayed by ELISA using a monoclonal antibody (OA-1). Total
aggrecan content was analyzed by an Alcian blue precipitation method
measuring sulfated glycosaminoglycan (sGAG) and by an ELISA using
the monoclonal antibody 1-F21 recognizing a peptide sequence in the
keratan sulfate domain. Kruskal-Wallis one way analysis of variance on
rank (Dunn’s method) was used for multiple group comparisons; P< 0.05
was considered signiﬁcant. Spearman rank order correlation (rS) was
used for comparisons.
Results: Median concentrations of aggrecan ARGS fragments (pmol/ml
SF) were elevated in all groups compared to the REF (Table I). The largest
elevation (177-fold) was seen in the acute arthritis group, while the knee
injury group had a 13-fold elevation and the OA group a 9-fold elevation.
Subdivision of the knee injury group showed that elevation of the ARGS
concentration in the knee injury group all occurred in the time span of
0−8 weeks after injury (KI-1) which was 130-fold elevated compared to
the reference. The release of ARGS fragments into the synovial ﬂuid
thereafter did not differ from REF. The SF ARGS concentration correlated
positively with the overall aggrecan content measured by Alcian blue
precipitation (rS = 0.687) and by the 1-F21 ELISA (rS = 0.667). In contrast
to the results of the ARGS immunoassay, when using the Alcian Blue
precipitation method only the AA and KI-1 groups differed in aggrecan
concentration from the REF group, and no differences between groups
were seen when using the 1-F21 assay (Table I).
Conclusions: The observed differences in ARGS concentration in syn-
ovial ﬂuid between the diagnostic groups showed that the aggrecanase
cleavage at the 373Glu-374Ala bond in the interglobular domain of ag-
grecan is enhanced in joint pathology, most markedly in acute arthritis
and early after knee injury, but also in knee OA. In contrast to methods
quantifying human SF total aggrecan (e.g. by sGAG measurements),
quantiﬁcation of ARGS fragments generated by aggrecanases is clearly
a more powerful tool in distinguishing healthy from diseased and injured
joints. The ARGS ELISA method could be used for monitoring disease
progression, predicting clinical outcomes and following the effects of
treatment.
Table I: Human SF median concentrations (ranges) of ARGS, sGAG and aggrecan
ARGS ELISA Alcian blue precipitation 1-F21 ELISA
Diagn
groups
n pmol
ARGS/ml
Fold
diff
P < 0.05 n mg
sGAG/ml
Fold
diff
P < 0.05 n mg aggrecan/
ml
Fold
diff
P < 0.05
REF 26 0.5
(0.5−3.3)
1 na 26 61
(5−210)
1 na 22 132
(20−558)
1 na
AA 48 88.5
(0.5−961)
177 Y 47 88
(112−528)
1.44 Y 45 261
(12−1912)
1.98 N
1KI 192 6.6
(0.5−946)
13 Y 191 74
(5−728)
1.21 N 189 104
(0.2−1340)
0.79 N
KI-1 64 64.9
(0.5−946)
130 Y 64 121
(39−728)
1.98 Y 62 178
(44−1340)
1.35 N
KI-2 58 0.5
(0.5−266)
1 N 58 63
(16−317)
1.03 N 57 87
(14−759)
0.66 N
KI-3 70 0.5
(0.5−166)
1 N 69 59
(5−245)
0.97 N 70 87
(0.2−791)
0.66 N
OA 29 4.6
(0.5−318)
9 Y 29 58
(8−201)
0.95 N 29 127
(12−482)
0.96 N
REF, knee healthy reference; AA, acute arthritis; KI, knee injury; KI-1, knee injury subgroup (SF aspiration
0−8 weeks after injury); KI-2, knee injury subgroup (SF aspiration 9−52 weeks after injury); KI-3, knee injury
subgroup (SF aspiration >52 weeks after injury); OA, knee osteoarthritis.
A38 RELATIONSHIPS BETWEEN CARTILAGE MRI MARKERS,
BIOCHEMICAL MARKERS, AND PAIN
E.B. Dam, I. Byrjalsen, M.A. Karsdal. Nordic Bioscience, Herlev,
DENMARK
Purpose: The pathogenesis of osteoarthritis (OA) is a complicated line
of events in the whole joint, eventually leading to pain and disability. Pain
is one of the most critical symptoms of osteoarthritis (OA) and a central
clinical end goal. However, the sources of pain are elusive and not well
understood – making treatment development challenging. Furthermore,
precise quantiﬁcation of pain is challenging in clinical trials, causing sur-
rogate markers to be desirable. We investigated the association between
pain and knee cartilage markers from magnetic resonance imaging (MRI)
as well as biochemical markers of bone and cartilage turnover.
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Methods: The 21-month longitudinal study included 159 subjects
prospectively selected as representative for the general population. From
these, only those over 30 years at follow-up were included to ensure a
homogeneous population. In total, 123 completed the study, age 58±14,
BMI 26±4, 47% female, and 54% with OA (Kellgren and Lawrence,
KL 1). Radiographs were acquired in a load-bearing semi-ﬂexed po-
sition using the SynaFlex (Synarc) and joint space width (JSW) was
measured. MRI scans with near-isotropic voxels were acquired from a
Turbo 3D T1 sequence from a 0.18T Esaote scanner (40º FA, TR 50ms,
TE 16ms, scan time 10 minutes, resolution 0.7mm×0.7mm×0.8mm)
and markers for volume, thickness, smoothness, homogeneity, and cur-
vature were quantiﬁed in a fully automatic computer-based framework.
Bone resorption was measured by the biochemical marker serum CTX-I
(C-terminal telopeptide of collagen type I) and cartilage degradation by
urine CTX-II (collagen type II, sample acquired as second morning void).
Pain was quantiﬁed by a visual assessment scale (VAS). Radiograph and
MRI markers were averaged for left and right medial compartments and
MRI markers were the sum of tibial and femoral compartments. Cross-
sectional biomarker scores and longitudinal changes over 21 months
were tested for association with pain and evaluated by correlation (r),
t-test of whether scores are higher in the group with pain (p), and odds
ratio for high scores relating to pain (OR).
Results: For all markers, the results are listed in Table 1. Cross-
sectionally at follow-up, BMI and CTX-II were associated with pain,
whereas age, JSW and homogeneity were borderline associated. Lon-
gitudinally, the changes from baseline to follow-up were borderline asso-
ciated with pain at follow-up for homogeneity and CTX-II. For CTX-II and
homogeneity this persisted after linear correction for gender and age (GA
cor).
Biomarker associations with pain, cross-sectional (C) and longitudinal (L)
r (C) p (C) OR (C) r (L) p (L) OR (L)
Age 0.21 0.053 3.8 *
Gender 0.02 0.445 1.4
BMI 0.26* 0.021* 3.3* −0.10 0.288 1.9
JSW −0.19 0.062 3.1* −0.09 0.737 1.2
CTX-I −0.16 0.028* 2.9 0.09 0.129 2.3
CTX-II 0.29** 0.001** 7.1** 0.05 0.077 3.2*
Volume −0.13 0.681 1.5 −0.16 0.063 2.3
Thickness −0.19 0.425 1.3 −0.14 0.866 0.9
Smoothness −0.13 0.936 0.9 −0.05 1.000 1.1
Homogeneity 0.22* 0.090 2.3 0.20 0.043* 3.3*
Curvature −0.02 0.549 1.4 0.06 0.973 0.7
CTX-II (GA cor) 0.28* 0.003** 7.1* 0.05 0.077 3.2*
Hom. (GA cor) 0.23* 0.099 2.3 0.20 0.043* 3.3*
Conclusions: The results in this study indicated that pain was associated
with the biochemical marker for cartilage breakdown (CTX-II) rather
than bone turnover (CTX-I). Furthermore, pain was associated with
the cartilage marker related to internal structure (homogeneity) rather
than denudation (volume or thickness). Combined, these results may
indicate that early stage cartilage breakdown should not be ignored
by treatment development targeting pain prevention. Measurement of
pain in longitudinal clinical studies is challenging due to poor precision
and confounding effects. Therefore, the cross-sectional and longitudinal
associations between pain and cartilage homogeneity (that has inter-scan
RMS CV 1.0%) merits further research to reveal whether homogeneity
may be a suitable surrogate marker for pain.
A39 ALTERED BONE TYPE I COLLAGEN TURNOVER AND
MATURATION ARE ASSOCIATED WITH INCREASED
CARTILAGE DEGRADATION IN PATIENTS WITH
OSTEOGENESIS IMPERFECTA (OI)
P. Garnero1, A-M. Schott2, G. Chevrel2. 1Synarc SAS, Inserm Research
Unit 664, E. Herriot Hospital, Department of Rheumatology, Lyon,
FRANCE, 2E. Herriot Hospital, Department of Rheumatology, Lyon,
FRANCE
Purpose: Altered subchondral bone remodeling and structure have been
suggested to play a role in the development of osteoarthritis (OA). Recent
animal studies have shown progressive articular cartilage degradation
in a mouse model of osteogenesis imperfecta (OI), a disease caused
by mutations in type I collagen (Col I) genes which are associated with
abnormal bone matrix. The aim of this study was to investigate whether
adult patients with OI used as a human model of bone Col-I defect, are
characterized by increased cartilage type II collagen (Col-II) degradation.
Methods: Sixty four patients with mild OI (25 women, 39 men; mean
age (SD): 36.2 (11.6) year) participating in a randomized study and 64
sex and age matched healthy controls were included. In patients with OI
and controls, we assessed the following bone Col-I and cartilage Col-II
parameters using speciﬁc biochemical markers: (1) Col I synthesis by
serum N-propeptide (PINP), (2) Col-I degradation by urinary fragments
of the helical domain of Col-I (Helix-I), (3) Col-I maturation by the
urinary ratio of native (a CTX-I) to isomerized (b CTX-I) aspartic acid
of Col-I C-telopeptide (a/b CTX-I). Isomerization is a post-translational
modiﬁcation of Col I reﬂecting the degree of bone matrix maturation
which has shown to be associated with altered structure, a high urinary
a/b CTX-I ratio being indicative of lower bone matrix maturation and
(4) Col-II degradation by urinary C-terminal telopeptide fragments (CTX-
II).
Results: As shown on the table, compared to healthy controls, adults
with OI had signiﬁcantly decreased bone Col-I synthesis (lower PINP),
increased bone Col-I degradation (higher Helix-I), decreased bone Col-I
maturation (higher a/b CTX-I ratio) and a marked increase in cartilage Col-
II degradation (high CTX-II). In patients with OI, urinary CTX-II correlated
with Helix-I, (r = 0.48, <0.0001) suggesting an association between bone
Col I and cartilage Col II degradation.
Conclusions: Cartilage type II collagen degradation is increased in a
human model of bone type I collagen defect. These data are in agreement
with animal studies suggesting that altered subchondral bone remodeling
and structure may be involved in the development of OA.
Subjects PINP
(ng/ml)
Helix-I
(mg/mmol Cr)
a/b CTX-I CTX-II
(ng/mmol Cr)
OI (n = 64) 32.3±19.8* 67.7±40.0* 2.04±0.72* 460±576*
Controls (n = 64) 41.8±13.5 42.8±19.4 1.37±0.43 143±62
*p< 0.001 vs controls; results are means±SD.
A40 PROTEOMIC IDENTIFICATION OF SECRETED BIOMARKERS
IN AN EXPLANT MODEL OF EARLY OSTEOARTHRITIS
A.L. Clutterbuck1, J.R. Smith2, D. Allaway3, P. Harris3, A. Mobasheri1.
1School of Veterinary Medicine and Science, University of Nottingham,
Nottingham, UNITED KINGDOM, 2Bruker Daltonics Limited, Coventry,
UNITED KINGDOM, 3WALTHAM Centre for Pet Nutrition, Melton
Mowbray, UNITED KINGDOM
Purpose: The molecular changes that occur in the early stages of
osteoarthritis (OA) are poorly understood. The aim of this study was to
use a targeted proteomic approach aimed at identiﬁcation of secreted
biomarkers from equine cartilage explants stimulated with recombinant
equine interleukin-1 beta (Il-1b).
Methods: Equine articular cartilage was obtained from weight bearing
regions of metatarsophalangeal joints of horses euthanized for purposes
other than for research. Full depth cartilage discs were excised with a
biopsy punch and washed extensively in PBS and serum free DMEM.
Explants were either incubated alone (control), or with Il-1b (10 ng×ml−1)
at 37ºC for 5 days. Supernatants were then removed and frozen before
trypsin digestion overnight at 37ºC. The reaction was stopped with formic
acid and the samples were stored at −80ºC until proteomic analysis by
ESI (Electrospray Ionisation) mass spectrometry. Peptides were sepa-
rated on a C18 pepmap column using a Dionex U3000 chromatography
platform and detected in a Bruker HCT PTM discovery ion trap instrument.
The four most abundant peptides in each MS scan were selected for
fragmentation. Using MASCOT search engine the fragment patterns
for each were compared to the mammalian entries in the SwissProt
database. The modiﬁcations incorporated into the search were: ﬁxed
carbamidomethyl cysteine, variable oxidation of methionine and variable
deamidation of asparagine and glutamine residues.
Results: Comparative proteomic analysis of the supernatants identiﬁed
a number of relevant proteins. Tryptic peptides originating from aggrecan
core protein, cartilage oligomeric matrix protein (COMP), ﬁbronectin,
ﬁbromodulin, thrombospondin-1 (TSP-1) and matrix metalloproteinases
MMP-1 and MMP-3 were detected. Several novel and unexpected se-
creted proteins were also identiﬁed including clusterin, cartilage interme-
diate layer protein-1 (CILP-1) and chondroadherin (CHAD) precursor.
Conclusions: This study has highlighted the presence of several novel
biomarkers in the supernatants of cartilage explants stimulated with Il-1b.
Many of the identiﬁed proteins have putative matrix functions including
participation in cell-matrix and matrix-matrix interactions (i.e. ﬁbronectin,
TSP-1, COMP, CHAD), matrix turnover (MMP-1, MMP-3) and extracellular
